Compare GSK plc (GSK) vs J M Smucker Co (SJM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs J M Smucker Co — how do they compare? GSK plc trades at $52.85 (market cap $101.34B), while J M Smucker Co trades at $109.02 (market cap $11.65B). The key difference: GSK plc is far larger — about 8.7× J M Smucker Co's market cap, and J M Smucker Co pays the higher dividend (4.04%). Which is the better fit depends on your goals.
| GSK | SJM | |
|---|---|---|
Market Cap | $101.34B | $11.65B |
Sector | Health | Consumer Staples |
52-Week High | $61.18 | $117.05 |
52-Week Low | $36.20 | $89.53 |
Enterprise Value | $121.95B | $18.68B |
Dividend Yield | 3.49% | 4.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
J.M. Smucker (SJM) trades at $113.00, up 3.85% today, with a bearish technical signal despite recent earnings beats. The company reported a net loss of $1.23 billion for 2025, with negative profit margins, though revenue grew to $8.73 billion. Analyst consensus is a Buy with a $123.18 price target, supported by strong cash flow and a 4% dividend yield. Key growth drivers include Uncrustables and coffee brands, while fiscal 2027 sales are expected to decline 3-4%.
SJM presents a mixed outlook: valuation appears reasonable with a P/E of 22.05, but profitability concerns and high debt pose risks. Near-term catalysts include cost controls and brand innovation, yet competitive pressures and weak sales guidance may limit upside. The stock offers income via dividends, but investors should weigh execution risks against potential margin recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
